MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/svn-2025-004198

Медицинская библиотека · Stroke and vascular neurology · 2026

Efficacy and safety of edaravone sublingual tablet for patients with cerebral small vessel disease-related cognitive impairment: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial.

Ye Qing, Ling Weidong, Chen Haifeng, Cheng Yue, Huang Lili, Mo Yuting, Zhang Xin, Yu Linjie, Meng Hailan, Qian Lai, Rong Rong, Zhu Xiaolei, Xu Yun

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Cerebral small vessel disease (CSVD) represents a leading aetiology of vascular cognitive impairment, yet effective treatments for CSVD-related cognitive impairment (CSVD-CI) are limited. Although edaravone has shown potential in alleviating CSVD's pathophysiological changes, its efficacy in CSVD-CI remains underexplored, partly due to the lack of a suitable long-term dosage form.

AIM: This trial aims to assess the efficacy and safety of edaravone sublingual tablets (EST) for cognitive impairment in patients with CSVD.

METHODS AND

DESIGN

This multicentre, randomised, double-blind, placebo-controlled trial will enrol patients with CSVD-CI, randomly assigning them to receive either EST or placebo for 24 weeks of treatment with concurrent follow-up, followed by an additional 24-week post-treatment follow-up period. Cognitive function, safety, MRI-based CSVD burden, cerebral arterial endothelial function and immune-mediated inflammation will be assessed. The primary outcome is the between-group difference in Montreal Cognitive Assessment score changes from baseline to week 48, along with adverse event incidence. Secondary outcomes include changes in cognitive domain scores, CSVD burden, deep regional cerebral perfusion and levels of glial fibrillar acidic protein (GFAP), neurofilament light chain and inflammatory factors in peripheral blood from baseline to weeks 24 and 48.

DISCUSSION: This trial will evaluate the efficacy and safety of EST in patients with CSVD-CI, potentially offering a new treatment strategy for this condition.

Для цитирования: Ye Qing, Ling Weidong, Chen Haifeng, Cheng Yue, Huang Lili, Mo Yuting, Zhang Xin, Yu Linjie, Meng Hailan, Qian Lai, Rong Rong, Zhu Xiaolei, Xu Yun. Efficacy and safety of edaravone sublingual tablet for patients with cerebral small vessel disease-related cognitive impairment: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial.. Stroke and vascular neurology. 2026. DOI: 10.1136/svn-2025-004198.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.